Opioid Pain Articles & Analysis
34 news found
Cebranopadol is the first and only dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist (dual-NMR) analgesic in clinical development for the treatment of moderate to severe pain, as well as opioid use disorder (OUD). ...
A new study published in Proceedings of the National Academy of Sciences (PNAS) indicates, “Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inammatory pain with fewer side eects.” Researchers used ...
These data suggest that cebranopadol has a lower potential for abuse versus both C-II and C-IV opioids. Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain. ...
Certain buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been recently associated with numerous serious oral health problems requiring medical intervention. ...
Substance use is an escalating crisis in the United States, with opioid-related drug overdose deaths rising above 100,000 in 2021.1 The standard of care for treating opioid use disorder (OUD) is medication for opioid use disorder (MOUD), including opioid receptor agonists and antagonists. ...
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 20201 More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in ...
We believe, before long, we will get the attention of large pharmaceutical companies looking to collaborate with us as we move towards the clinic and establish our technology as a leading edge non-opioid treatment for inflammation and neuropathic pain,” said Dean Petkanas, CEO of Neuropathix. ...
Key data highlights with the Evoke® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation. ...
BioWave’s technology has helped professional and college athletes, veterans and others suffering from chronic pain, get closer to a pain-free life and return to daily activities without the use of opioids. ...
DEA’s National Prescription Drug Take Back Day reflects DEA’s commitment to Americans’ safety and health, encouraging the public to remove unneeded medications from their homes as a measure of preventing medication misuse and opioid addiction from ever starting. The Berkshire team supports the DEA’s commitment to making communities safer and healthier. ...
In the past decade, pharmaceutical companies have been reluctant to re-address pain treatments following the opioids crisis. However, we see a change on the horizon. Neuropathix has designated proprietary, cannabinoid-derivative compound KLS-13019 as lead drug candidate for the treatment of neuropathic pain, a viable alternative to ...
The initial intended use for COPA will include the delivery of opioids for the treatment of chronic pain and the delivery of methadone in Medication Assisted Therapy for the treatment of opioid use disorder. ...
The Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of controlled oral liquid medications for chronic pain and opioid addiction medication assisted therapy, as the Company believes they have the greatest need for the benefits of COPA’s features. ...
KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in pre-clinical animal studies. ...
There is a high unmet medical need in chronic pain, particularly among patients with concomitant opioid use problems. If approved, Buvidal could become an important therapeutic option for the management of chronic pain, adding to the current indication of treating opioid dependence”, says Dr. ...
The pharmacokinetic profile of QIXLEEF™ is well indicated to help manage short episodes of pain such as breakthrough pain and will offer patients and physicians a viable, safer, and non-opioid option for pain management." ...
Three overarching features combine to make the COPA technology unique: security, compliance support (metrics) with remote monitoring and precise liquid dispensing. Chronic pain and opioid addiction medication assisted therapy have been identified as potential indications with the greatest need for the benefits of these features. ...
QIXLEEF™, with its innovative and proprietary dosing data, provides fast acting relief from pain, offering patients a viable, safer, and non-opioid option for pain management. ...
Adding to the equation is the off-label use of opioids and gabapentinoids for chronic and neuropathic pain as a result of the unmet medical need and no FDA approved non-opioid drug to treat chronic and neuropathic pain, specifically Chemotherapy-induced peripheral neuropathy (CIPN). ...
“We applaud those dedicated to raising awareness of the global overdose and addiction crisis as we all grapple with the challenges associated with pain medication, including the dangers of misuse, abuse and diversion of medications," said John Timberlake, Chief Executive Officer of Berkshire Biomedical. ...